期刊文献+

肝细胞癌移植术后肿瘤复发的评估、预防和治疗 被引量:2

Preoperative and postoperative prognostic indicators of recurrence of hepatocellular carcinoma following liver transplantation
原文传递
导出
摘要 肝移植是经过选择的肝癌患者有效的治疗方法之一,但是约有20%的肿瘤复发率限制了肝癌、肝硬化移植术后的长期生存.尽管有些临床指标会强烈提示复发风险和术前肿瘤肝外转移,从而放弃肝移植.事实上,术后肿瘤复发往往是由于术前或术中出现肝外微转移病灶进一步发展的结果.由于器官的紧缺,肿瘤局部治疗以及外科肝部分切除术成为肝移植术前等待期间的桥梁.而且,更积极的外科切除包括切除肝肿瘤以及肝外孤立的转移灶.这些创造性方案是否能改变生存率目前还不清楚,需要长期的随访才能判定其效果. Liver transplantation is a valid treatment option for select patients with Hepatocellular Carcinoma HCC and end-stage liver disease. However, in approximately 20% of patients, recurrent HCC is the rate-limiting factor for longterm survival. Despite identification of clinical parameters that may stratify patients at high risk and exhaustive preoperative staging, cancer recurrence is likely the result of microscopic extrahepatic disease. With a desperate donor organ shortage, locoregional ablation techniques and resection are being employed in patients on the waiting list to serve as a bridge to OLT. Further more, some have advocated aggressive surgical resection of isolated metastasis in both the liver and extrahepatic viscera. Whether these creative strategies confer a survival advantage is unknown, requiring longterm follow-up to determine their efficacy.
作者 吴迪 郑虹
出处 《国际外科学杂志》 2010年第8期557-561,共5页 International Journal of Surgery
关键词 肝细胞癌 肝移植 复发 Hepatocellular Carcinoma Liver transplantation Recurrent
  • 相关文献

参考文献1

二级参考文献31

  • 1Llovet JM, Fuster J, Bruix J. Barcelona-clinic liver cancer group.The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10(2 Suppl 1):S115-120.
  • 2Podbielski J, Schoenberg L. Use of sirolimus in kidney transplantation. Prog Transplant 2001; 11:29-32.
  • 3Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP.Sirolimus renal function study group. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74:1560-1567.
  • 4Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: An overview. Liver Transpl 2001; 7:473-484.
  • 5Kahan BD, Stepkowski SM, Napoli KL, Katz SM, Knight RJ,Van Buren C. The development of sirolimus. The university of texas-jouston experience. Clin Transpl 2000:145-158.
  • 6Gaston RS. Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens. Transplant Proc 1999; 31-17S-22S.
  • 7McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355:376-377.
  • 8McAlister VC, Peltekian KM, Malatjalian DA, Colohan S,Macdonald S, Bitter-Suermann H, Macdonald AS. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7:701-708.
  • 9Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58:373-395.
  • 10Sherr CJ. G1 please progression: Cycling on cue. Cell 1994;79:551-555.

共引文献13

同被引文献17

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部